BlackRock
STRO icon

BlackRock’s Sutro Biopharma STRO Stock Holding History

BlackRock’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.8M Buy
232,684
+115,247
+98% +$2.08M ﹤0.01% 3765
2025
Q4 		$1.36M Sell
117,437
-51,351
-30% -$487K ﹤0.01% 4224
2025
Q3 		$1.47M Sell
168,788
-41,913
-20% -$357K ﹤0.01% 4190
2025
Q2 		$1.5M Sell
210,701
-409,777
-66% -$3.35M ﹤0.01% 4140
2025
Q1 		$4.04M Sell
620,478
-138,841
-18% -$2.19M ﹤0.01% 3721
2024
Q4 		$14M Buy
759,319
+57,707
+8% +$1.76M ﹤0.01% 3249
2024
Q3 		$24.3M Buy
701,612
+10,539
+2% +$413K ﹤0.01% 2902
2024
Q2 		$20.2M Buy
691,073
+120,882
+21% +$4.78M ﹤0.01% 2981
2024
Q1 		$32.2M Sell
570,191
-12,201
-2% -$539K ﹤0.01% 2711
2023
Q4 		$25M Sell
582,392
-16,268
-3% -$516K ﹤0.01% 2881
2023
Q3 		$20.8M Sell
598,660
-1,896
-0.3% -$82.6K ﹤0.01% 2925
2023
Q2 		$27.9M Buy
600,556
+98,474
+20% +$4.9M ﹤0.01% 2824
2023
Q1 		$23.2M Buy
502,082
+16,068
+3% +$1.02M ﹤0.01% 2898
2022
Q4 		$39.3M Buy
486,014
+85,177
+21% +$5.92M ﹤0.01% 2632
2022
Q3 		$22.2M Buy
400,837
+28,574
+8% +$1.69M ﹤0.01% 2975
2022
Q2 		$19.4M Sell
372,263
-620
-0.2% -$34.6K ﹤0.01% 3108
2022
Q1 		$30.6M Buy
372,883
+2,879
+0.8% +$274K ﹤0.01% 2892
2021
Q4 		$55.1M Buy
370,004
+4,356
+1% +$780K ﹤0.01% 2603
2021
Q3 		$69.1M Buy
365,648
+2,968
+0.8% +$564K ﹤0.01% 2442
2021
Q2 		$67.4M Buy
362,680
+52,483
+17% +$10.3M ﹤0.01% 2497
2021
Q1 		$70.6M Buy
310,197
+38,404
+14% +$9.11M ﹤0.01% 2394
2020
Q4 		$59M Buy
271,793
+67,037
+33% +$11.1M ﹤0.01% 2376
2020
Q3 		$20.6M Buy
204,756
+108,732
+113% +$10.3M ﹤0.01% 2844
2020
Q2 		$7.45M Buy
96,024
+29,949
+45% +$2.87M ﹤0.01% 3358
2020
Q1 		$6.74M Buy
66,075
+1,364
+2% +$143K ﹤0.01% 3207
2019
Q4 		$7.12M Buy
64,711
+309
+0.5% +$31.9K ﹤0.01% 3400
2019
Q3 		$5.85M Buy
64,402
+9,987
+18% +$1.01M ﹤0.01% 3434
2019
Q2 		$6.19M Buy
54,415
+22,848
+72% +$2.52M ﹤0.01% 3464
2019
Q1 		$3.6M Sell
31,567
-9,404
-23% -$978K ﹤0.01% 3524
2018
Q4 		$3.7M Buy
40,971
+6,981
+21% +$843K ﹤0.01% 3487
2018
Q3 		$5.1M Buy
+33,990
New +$5.13M ﹤0.01% 3504

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock's STRO Position: Q1 2026 in Review

BlackRock increased its Sutro Biopharma (STRO) stake by 98% in Q1 2026, buying an estimated $2.08M and bringing the position to 232,684 shares worth $5.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3765.

BlackRock first reported a position in STRO in Q3 2018 and has held it in 31 quarters since. The position peaked at $70.6M in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • BlackRock held 232,684 shares of Sutro Biopharma worth $5.8M as of Q1 2026.
  • BlackRock bought 115,247 Sutro Biopharma shares in Q1 2026, an estimated $2.08M.
  • Sutro Biopharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3765 holding.
  • BlackRock first reported a position in Sutro Biopharma in Q3 2018 and has held it in 31 quarters since.
  • BlackRock's Sutro Biopharma position peaked at $70.6M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.